Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

NCT ID: NCT07151001

Last Updated: 2025-09-02

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 922 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-01-01
• Study Completion Date: 2027-07-31

Brief Summary

In this pivotal trial, we aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in the primary care and endocrinology clinics. DR is one of the leading causes of blindness in the United States and other developed countries. Every individual with diabetes is at risk of DR. It does not show any symptoms until the disease is progressed to advanced stages. If the disease is caught at an early stage, it can be prevented, managed, or treated effectively. Currently, screening for DR is done by the Ophthalmologists, which is limited to areas with limited availability. This is also time-consuming and expensive. All of these can be complemented by automated screening and set up the screening in the primary care clinics.

Detailed Description

In this pivotal trial, we aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in the primary care and endocrinology clinics. DR is one of the leading causes of blindness in the United States and other developed countries. Every individual with diabetes is at risk of DR. It does not show any symptoms until the disease is progressed to advanced stages. If the disease is caught at an early stage, it can be prevented, managed, or treated effectively. Currently, screening for DR is done by the Ophthalmologists, which is limited to areas with limited availability. This is also time-consuming and expensive. All of these can be complemented by automated screening and set up the screening in the primary care clinics.

American Academy of Ophthalmology has suggested a 5-level DR disease severity scale (No DR, Mild DR, Moderate DR, Severe DR or Proliferative DR) based on the abnormalities in the retina such as microaneurysms, exudates, hemorrhages, intraretinal microvascular abnormalities (IRMA), and neovascularization. Automated screening for Diabetic Retinopathy has a potential to identify people at risk of developing sight-threatening disease and save millions of dollars in healthcare costs. To accomplish this, it is crucial to perform large scale population screening to identify the individuals with mild or early DR and better predict those at risk of developing late stage DR. A system that takes advantage of telemedicine with automated DR screening in reaching the mass populations in both urban and rural areas with the patient convenience is currently not widely available.

Considering this urgent need, iHealthScreen has developed an automated software tool for DR screening which is based on artificial intelligence (AI) and make it widely available in both urban and remote/rural areas and for large-scale screening through a telemedicine platform, and thereby have the potential to prevent blindness in diabetic patients.

Conditions

Diabetes; Diabetic Retinopathy

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

One Group

One Cohort

No intervention

Intervention Type: DEVICE

No intervention. Evaluate the automated DR screening software.

Interventions

No intervention

No intervention. Evaluate the automated DR screening software.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Age of Subjects: Patients ≥ 22 years of age.
• Gender of Subjects: Both males and females will be invited to participate.
• Subjects with diabetes (A1C level ≥ 6.5).
• Subjects must be willing and are able to comply with clinic visit, understand the study-related procedures/provisions, and provide signed informed consent.

Exclusion Criteria

• Unable to understand the study, Our unable to or unwilling to sign the informed consent
• Previously diagnosed with macular edema, any form of diabetic retinopathy, radiation retinopathy, or retinal vein occlusion
• participants who are experiencing persistent vision loss, blurred vision, or other vision problems that should be evaluated by an eye care provider
• subjects whose retinal images were used in training, validating, or developing the device
• Currently participating in another investigational eye study or actively receiving investigational product for DR or DME.
• A condition that, in the opinion of the investigator, would preclude participation in the study;
• Contraindicated for imaging by fundus imaging systems used in the study because of hypersensitivity to light, recently underwent photodynamic therapy, or was taking medication that causes photosensitivity.

• Minimum Eligible Age: 22 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institutes of Health (NIH)

NIH

Sponsor Role: collaborator

iHealthScreen Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alauddin Bhuiyan, PhD

Role: PRINCIPAL_INVESTIGATOR

iHealthScreen Inc

Locations

iHealthScreen Inc.

Richmond Hill, New York, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Alauddin Bhuiyan

Role: CONTACT

bhuiyan@ihealthscreen.org

718-926-9000

Fariha Nuha, BS (Comp. Biology)

Role: CONTACT

fariha@ihealthscreen.org

718-912-0837

Other Identifiers

2024-02-iPredict-DR

Identifier Type: -

Identifier Source: org_study_id